Cargando…

Exosomes in multiple myeloma: from bench to bedside

Multiple myeloma (MM) remains an incurable plasma cell malignancy that develops in the bone marrow (BM). This BM is partially responsible for protecting the MM cells against current standard-of-care therapies and for accommodating MM-related symptoms such as bone resorption and immune suppression. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menu, Eline, Vanderkerken, Karin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653045/ https://www.ncbi.nlm.nih.gov/pubmed/35271699 http://dx.doi.org/10.1182/blood.2021014749

Ejemplares similares

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
por: Favreau, Mérédis, et al.
Publicado: (2016)

Pathogenesis of bone disease in multiple myeloma: from bench to bedside
por: Terpos, Evangelos, et al.
Publicado: (2018)

Novel strategies to target the ubiquitin proteasome system in multiple myeloma
por: Lub, Susanne, et al.
Publicado: (2015)

Exosomes and Hepatocellular Carcinoma: From Bench to Bedside
por: Sasaki, Reina, et al.
Publicado: (2019)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2013)

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells
por: Wang, Jinheng, et al.
Publicado: (2015)

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
por: Hu, Jinsong, et al.
Publicado: (2012)

Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
por: Oudaert, Inge, et al.
Publicado: (2022)

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma
por: Wang, Jinheng, et al.
Publicado: (2016)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
por: Bieghs, Liesbeth, et al.
Publicado: (2010)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

The genetic landscape of 5T models for multiple myeloma
por: Maes, Ken, et al.
Publicado: (2018)

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts
por: Faict, Sylvia, et al.
Publicado: (2018)

Identification of the immune checkpoint signature of multiple myeloma using mass cytometry‐based single‐cell analysis
por: Wang, Jinheng, et al.
Publicado: (2020)

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma
por: Vlummens, Philip, et al.
Publicado: (2019)

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
por: De Smedt, Eva, et al.
Publicado: (2018)

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
por: Yan, Siyang, et al.
Publicado: (2019)

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
por: Verheye, Emma, et al.
Publicado: (2022)

Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2014)

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
por: Muylaert, Catharina, et al.
Publicado: (2022)

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
por: Bieghs, Liesbeth, et al.
Publicado: (2016)

Exosomes and circular RNAs: promising partners in hepatocellular carcinoma from bench to bedside
por: Hu, Mengyuan, et al.
Publicado: (2023)

Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Sepsis: From Bench to Bedside
por: Silva, Eliézer, et al.
Publicado: (2008)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
por: De Beck, Lien, et al.
Publicado: (2018)

Olutasidenib: from bench to bedside
por: Venugopal, Sangeetha, et al.
Publicado: (2023)

Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

Endogenous Lipid Carriers—Bench-to-Bedside Roadblocks in Production and Drug Loading of Exosomes
por: Richards, Terjahna, et al.
Publicado: (2023)

Research in Sickle Cell Disease: From Bedside to Bench to Bedside
por: Salinas Cisneros, Gabriel, et al.
Publicado: (2021)

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Variable ventilation from bench to bedside
por: Huhle, Robert, et al.
Publicado: (2016)

Biology of Cholangiocytes: From Bench to Bedside
por: Yoo, Kyo-Sang, et al.
Publicado: (2016)

CDG Therapies: From Bench to Bedside
por: Brasil, Sandra, et al.
Publicado: (2018)

Dystonia and Cerebellum: From Bench to Bedside
por: Morigaki, Ryoma, et al.
Publicado: (2021)

Alcohol in Psoriasis—From Bench to Bedside
por: Szentkereszty-Kovács, Zita, et al.
Publicado: (2021)

From bench to bedside
por: Verdant, Colin L
Publicado: (2012)

Indirect Calorimetry: From Bench to Bedside
por: Gupta, Riddhi Das, et al.
Publicado: (2017)

Drug addiction: from bench to bedside
por: Cheron, Julian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_575lju3mdo50tc6tag5lt8sqrl